Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Best frontline options for advanced follicular lymphoma

Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

Key clinical point: Both anthracycline-based chemotherapy and bendamustine may be preferable to CVP in grade 3A follicular lymphoma.

Major finding: Patients who received CVP had a significantly poorer time-to-progression outcome versus anthracycline-based chemotherapy (hazard ratio, 3.22; 95% CI, 1.26-8.25; P = .01), while there was no significant difference between bendamustine and anthracyclines.

Study details: A multicenter analysis including 103 patients with advanced stage grade 3A follicular lymphoma.

Disclosures: The authors reported disclosures related to Exelixis, OncoSec, Geron, Jazz, Kite, Juno, Lentigen Technology, Sanofi-Genzyme, Celgene, Takeda, Otsuka, Spectrum, Merck, and Astellas, among others.

Read the article.

Citation:

Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.